Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis
作者： K. M. Myhr , T. Riise , F. E. G. Lilleas , T. G. Beiske , E. G. Celius
关键词:
摘要: Objective: To evaluate the efficacy and safety of interferon-α2a (IFN-α2a) in relapsing-remitting MS (RRMS). Background: Several immune-modulating therapy regimens IFN-α have shown varying results MS. A recent pilot study suggested benefits from IFN-α2a. Methods: Ninety-seven patients were randomized to receive subcutaneous injections placebo (33 patients) or 4.5 million international units (mIU) (32 9.0 mIU IFN-α2a three times weekly for 6 months, with a further months follow-up. Monthly gadodiamide-enhanced MRI was primary method evaluating efficacy. Results: treatment resulted fewer new lesions during period ( p 2.5 higher than = 0.0004), but difference disappeared The total number (mean) increased by 4.78 placebo, 0.86 IFN-α2a, 0.28 0.030). No effect on exacerbation rate, progression disability, quality life detected. Nine discontinued treatment, five because adverse events. Conclusions: significantly reduced disease activity as measured MRI, within after discontinuation treatment. long-term more using disability outcome measure is needed clinical impact.
sci-hub.st 参考文章(28)
U. Hennes, W. Jucker, E.A. Fischer, Th. Krummenacher, A.V. Palleroni, P.W. Trown, S. Linder-Ciccolunghi, M. Rainisio, The detection of antibodies to recombinant interferon alfa-2a in human serum Journal of Biological Standardization. ,vol. 15, pp. 231- 244 ,(1987) , 10.1016/0092-1157(87)90026-6
B. G. WEINSHENKER, G. P. A. RICE, J. H. NOSEWORTHY, W. CARRIERE, J. BASKERVILLE, G. C. EBERS, The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain. ,vol. 114, pp. 1057- 1067 ,(1991) , 10.1093/BRAIN/114.2.1057
D H Miller, F Barkhof, I Berry, L Kappos, G Scotti, A J Thompson, Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 54, pp. 683- 688 ,(1991) , 10.1136/JNNP.54.8.683
E. Kinnunen, T. Timonen, T. Pirttilä, P. Kalliomäki, L. Ketonen, E. Matikainen, R. Sepponen, J. Juntunen, Effects of recombinant α‐2b‐interferon therapy in patients with progressive MS Acta Neurologica Scandinavica. ,vol. 87, pp. 457- 460 ,(2009) , 10.1111/J.1600-0404.1993.TB04136.X
L. F. Kastrukoff, J. J. Oger, S. A. Hashimoto, S. L. Sacks, D. K. Li, M. R. Palmer, R. A. Koopmans, A. J. Petkau, J. Berkowitz, D. W. Paty, Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology. ,vol. 40, pp. 479- 479 ,(1990) , 10.1212/WNL.40.3_PART_1.479
L. Durelli, M. R. Bongioanni, B. Ferrero, R. Ferri, D. Imperiale, G. B. Bradac, M. Bergui, M. Geuna, L. Bergamini, B. Bergamasco, Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis Disease activity resumes after stopping treatment Neurology. ,vol. 47, pp. 123- 129 ,(1996) , 10.1212/WNL.47.1.123
K. P. Johnson, B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, T. Vollmer, L. P. Weiner, J. S. Wolinsky, , Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial Neurology. ,vol. 45, pp. 1268- 1276 ,(1995) , 10.1212/WNL.45.7.1268
R. L. Knobler, H. S. Panitch, S. L. Braheny, J. C. Sipe, G.P.A. Rice, J. R. Huddlestone, G. S. Francis, C. J. Hooper, R. M. Kamin-Lewis, K. P. Johnson, M. B.A. Oldstone, T. C. Merigan, Systemic alpha‐interferon therapy of multiple sclerosis Neurology. ,vol. 34, pp. 1273- 1273 ,(1984) , 10.1212/WNL.34.10.1273
L. Durelli, M. R. Bongioanni, R. Cavallo, B. Ferrero, R. Ferri, M. F. Ferrio, G. B. Bradac, A. Riva, S. Vai, M. Geuna, L. Bergamini, B. Bergamasco, Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. ,vol. 44, pp. 406- 406 ,(1994) , 10.1212/WNL.44.3_PART_1.406
S. Izumo, I. Goto, Y. Itoyama, T. Okajima, S. Watanabe, Y. Kuroda, S. Araki, M. Mori, M. Nagataki, S. Matsukura, T. Akamine, M. Nakagawa, I. Yamamoto, M. Osame, Interferon-alpha is effective in HTLV-I-associated myelopathy A multicenter, randomized, double-blind, controlled trial Neurology. ,vol. 46, pp. 1016- 1021 ,(1996) , 10.1212/WNL.46.4.1016